Posted: 04/30/2025 07:25 am
DENTSPLY SIRONA Inc. (NASDAQ: XRAY), a prominent player in the dental equipment and supplies industry, has been recently under the spotlight, not for its innovations but due to executive compensation amid shareholder investigations. The company's current market movements are of particular interest to both investors and industry watchers, not only because of its fluctuating share price but also because of broader corporate governance issues.
Recent executive compensation at DENTSPLY SIRONA has drawn attention, especially as scrutiny increases with ongoing legal investigations. For the fiscal year 2024, Glenn G. Coleman, the Executive Vice President and Chief Financial Officer, received a total compensation package valued at approximately $3.14 million. This package included a base salary of $568,075, stock awards amounting to $1.93 million, and option awards worth $625,116, with no bonuses or incentive plan compensation included.^[1^]
In contrast, Andreas G. Frank, in his role as Executive Vice President and Chief Business Officer for 2023, received a total of $3.75 million.^[2^] His compensation also relied heavily on stock awards, emphasizing the company's focus on long-term value alignment, albeit at a time when investors are closely watching for transparency and accountability.
The intricacies of executive compensation packages are further exemplified by DENTSPLY's approach in previous years. In 2022, former CFO Barbara W. Bodem’s total compensation was $2.61 million, predominantly from stock awards^[3^], reflecting a similar remuneration style despite the company's shifting financial landscape, including past issues that have since led to ongoing investigations.
Recent legal probes, particularly those initiated by firms such as Bronstein, Gewirtz & Grossman, LLC, and Bragar Eagel & Squire, P.C., are investigating potential claims against DENTSPLY regarding actions prior to May 2021.^[4^] These investigations stem from alleged breaches of fiduciary duties and financial missteps, complicating the perception of executive payouts even further.
The investigations have understandably instigated a ripple effect on DENTSPLY’s market standing. The company's stock recently traded at $13.95, considerably below its 52-week high of $30.78, reflecting market skepticism potentially fueled by these legal undertakings and internal corporate issues.^[5^]
DENTSPLY's current strategic direction, including the review of its Wellspect Healthcare business,^[6^] adds further dimensions to the ongoing discussion about future stability and executive decision-making. These moves are being closely monitored to assess how the company will resolve these challenges and what impact these strategies will have on long-term shareholder value.
The unfolding scenario at DENTSPLY is a cautionary tale of how corporate governance issues, particularly involving executive compensation, can have far-reaching implications. As the investigations proceed, stakeholders remain vigilant about the outcomes and their potential impacts on the company's financial health and market reputation.
:
1. "DENTSPLY SIRONA Inc. Executive Compensation for Glenn G. Coleman, 2024." U.S. Securities and Exchange Commission. [SEC Filing](https://www.sec.gov/Archives/edgar/data/818479/000114036125013040/0001140361-25-013040-index.htm).
2. "Executive Compensation for Andreas G. Frank, 2023." U.S. Securities and Exchange Commission. [SEC Filing](https://www.sec.gov/Archives/edgar/data/818479/000114036124019103/0001140361-24-019103-index.htm).
3. "Compensation Disclosure for Barbara W. Bodem, 2022." U.S. Securities and Exchange Commission. [SEC Filing](https://www.sec.gov/Archives/edgar/data/818479/000119312523101351/0001193125-23-101351-index.htm).
4. "Legal Investigations Announcements by Bronstein, Gewirtz & Grossman, LLC." Access Newswire. Various Dates, 2025. [Access Newswire](https://www.accessnewswire.com).
5. "Current Stock Price and Market Data for DENTSPLY SIRONA." Financial Snapshot, 2025.
6. "DENTSPLY SIRONA's Strategic Alternatives Review Announcement for Wellspect Healthcare." Globe Newswire. [Globe Newswire](https://www.globenewswire.com).
